Indeed, in a variety of models, a combination of therapeutic antibodies against PDL1 and VEGF has shown synergistic clinical benefit in tumor control vs. anti-VEGF or anti-PDL1 treatment alone or vs. anti-VEGF treatment combined with cytotoxic chemotherapeutic agents13,14,34,35. This evidence concerns the gene VEGFA and neoplasm.